GMVD · G Medical Innovations Holdings Ltd. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q4 '19 | Q4 '18 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - |
| R&D | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - |
| Total Operating Expenses | - | - | - | - | - | - | - |
| D&A | - | - | - | - | - | - | - |
| Operating Income | - | - | - | - | - | - | - |
| Interest Expense | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - |
| EPS - Basic | - | - | - | - | - | - | - |
| EPS - Diluted | - | - | - | - | - | - | - |
Balance Sheet
| Line item | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q4 '19 | Q4 '18 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $295.0K | $1.51M | $6.03M | $278.0K | $278.0K | - | $2.63M |
| Accounts Receivable | $441.0K | $1.33M | $1.49M | $717.0K | $1.42M | - | - |
| Inventory | $292.0K | $2.34M | $355.0K | $90.0K | $90.0K | - | - |
| Accounts Payable | - | - | - | $3.10M | - | - | - |
| Current Assets | $1.99M | $5.92M | $8.55M | $3.13M | $3.13M | - | - |
| Total Assets | $4.83M | $10.28M | $10.52M | $5.45M | $5.45M | - | - |
| Current Liabilities | $9.11M | $10.61M | $8.28M | $7.90M | $7.90M | - | - |
| Long-term Debt | - | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - | - |
| Stockholders' Equity | ($4.57M) | ($1.24M) | ($2.81M) | ($6.30M) | ($2.95M) | ($9.88M) | ($6.59M) |
| Retained Earnings | ($115.26M) | ($103.66M) | ($90.63M) | ($75.88M) | ($75.88M) | - | - |
Cash Flow
| Line item | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q4 '19 | Q4 '18 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - |
| Financing Cash Flow | - | - | - | - | - | - | - |
| CapEx | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - |
Ratios
| Metric | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q4 '19 | Q4 '18 |
|---|---|---|---|---|---|---|---|
| Profitability | |||||||
| Gross margin | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - |
| Return on assets | - | - | - | - | - | - | - |
| Return on equity | - | - | - | - | - | - | - |
| Return on invested capital | - | - | - | - | - | - | - |
| Liquidity | |||||||
| Current ratio | 0.22 | 0.56 | 1.03 | 0.40 | 0.40 | - | - |
| Quick ratio | 0.19 | 0.34 | 0.99 | 0.39 | 0.39 | - | - |
| Cash ratio | 0.03 | 0.14 | 0.73 | 0.04 | 0.04 | - | - |
| Leverage | |||||||
| Debt / Equity | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - |
| Equity multiplier | -1.06 | -8.29 | -3.74 | -0.87 | -1.85 | - | - |
| Liabilities / Assets | - | - | - | - | - | - | - |
| Efficiency | |||||||
| Asset turnover | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - |
| Valuation | |||||||
| P / E | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - |
| Growth | |||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - |
| Operating income growth (YoY) | - | - | - | - | - | - | - |
| Net income growth (YoY) | - | - | - | - | - | - | - |
| EPS growth (YoY) | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - |
| Book value growth (YoY) | -62.6% | 80.3% | 4.6% | - | 70.1% | -49.9% | - |
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing G Medical Innovations Holdings Ltd. against the 5 most active filers in the same SIC group.